ATE341312T1 - Orale pharmazeutische zusammensetzung mit verzögerter freisetzung - Google Patents

Orale pharmazeutische zusammensetzung mit verzögerter freisetzung

Info

Publication number
ATE341312T1
ATE341312T1 AT03291180T AT03291180T ATE341312T1 AT E341312 T1 ATE341312 T1 AT E341312T1 AT 03291180 T AT03291180 T AT 03291180T AT 03291180 T AT03291180 T AT 03291180T AT E341312 T1 ATE341312 T1 AT E341312T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
release pharmaceutical
delayed release
oral delayed
coating agent
Prior art date
Application number
AT03291180T
Other languages
English (en)
Inventor
Sandrine Salle
Emmanuel Guerin
Original Assignee
Ethypharm Sa
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa, Toray Industries filed Critical Ethypharm Sa
Application granted granted Critical
Publication of ATE341312T1 publication Critical patent/ATE341312T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03291180T 2003-05-20 2003-05-20 Orale pharmazeutische zusammensetzung mit verzögerter freisetzung ATE341312T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291180A EP1479383B1 (de) 2003-05-20 2003-05-20 Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung

Publications (1)

Publication Number Publication Date
ATE341312T1 true ATE341312T1 (de) 2006-10-15

Family

ID=33041114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03291180T ATE341312T1 (de) 2003-05-20 2003-05-20 Orale pharmazeutische zusammensetzung mit verzögerter freisetzung

Country Status (9)

Country Link
US (1) US9616071B2 (de)
EP (1) EP1479383B1 (de)
JP (1) JP5013871B2 (de)
CN (1) CN100475197C (de)
AT (1) ATE341312T1 (de)
CA (1) CA2525542C (de)
DE (1) DE60308828T2 (de)
ES (1) ES2272914T3 (de)
WO (1) WO2004103350A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
EP2127643A1 (de) * 2008-05-30 2009-12-02 Bayer Schering Pharma Aktiengesellschaft Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe
EP2198859A1 (de) 2008-12-17 2010-06-23 Losan Pharma GmbH Schmelzbeschichtete pharmazeutische Zusammensetzung mit Freisetzung
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
JP5780775B2 (ja) * 2011-02-18 2015-09-16 株式会社Ｌｔｔバイオファーマ プロスタグランジンｉ２誘導体を含有するナノ粒子
CN103127220B (zh) * 2011-12-05 2014-12-31 上海中医药大学 一种用于中药丹参浸膏粉或颗粒的防潮包衣方法
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
EP3904326A1 (de) 2014-11-18 2021-11-03 Insmed Incorporated Verfahren zur herstellung von treprostinil und treprostinilderivat-prodrugs
CN106822013B (zh) * 2015-11-30 2020-05-12 北京泰德制药股份有限公司 前列环素类似物缓释制剂
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4082549A4 (de) 2019-12-23 2023-09-06 Toray Industries, Inc. Arzneimittel zur verhinderung von dialyseänderung oder nierentod
MX2023013545A (es) 2021-06-16 2023-11-29 Toray Industries Metodo terapeutico para gato con enfermedad renal cronica.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
FI101344B1 (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
JPH01287019A (ja) * 1988-05-12 1989-11-17 Tanabe Seiyaku Co Ltd 徐放性製剤
JPH01287021A (ja) * 1988-05-13 1989-11-17 Shin Etsu Chem Co Ltd ワックス複覆薬剤の製造方法
JPH02225416A (ja) * 1989-02-28 1990-09-07 Toray Ind Inc ５，６，７―トリノル―４，８―インタ―ｍ―フェニレンＰＧＩ↓２誘導体の経口用製剤
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
JPH05309314A (ja) * 1992-05-07 1993-11-22 Sumitomo Pharmaceut Co Ltd コーティング方法
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
JP3471977B2 (ja) * 1995-06-02 2003-12-02 信越化学工業株式会社 液体状可塑剤を用いる無溶媒腸溶性コーティング剤で被覆した腸溶性製剤
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
AU6310898A (en) * 1997-03-14 1998-10-12 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
DE19808634A1 (de) * 1998-02-24 1999-08-26 Schering Ag Mantel für eine pharmazeutische Zusammensetzung
JP2000103732A (ja) 1998-07-28 2000-04-11 Tanabe Seiyaku Co Ltd 腸内適所放出型製剤
JP4969761B2 (ja) * 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
MXPA03000985A (es) * 2001-07-27 2004-04-02 Yamanouchi Pharma Co Ltd Composicion que comprende particulas finas de liberacion sostenida para tabletas de desintegracion rapida en la cavidad bucal y metodo de fabricacion de la misma.
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same

Also Published As

Publication number Publication date
US20070269506A1 (en) 2007-11-22
DE60308828D1 (de) 2006-11-16
CA2525542A1 (en) 2004-12-02
CN100475197C (zh) 2009-04-08
DE60308828T2 (de) 2007-05-24
CA2525542C (en) 2012-01-10
US9616071B2 (en) 2017-04-11
EP1479383B1 (de) 2006-10-04
JP5013871B2 (ja) 2012-08-29
EP1479383A1 (de) 2004-11-24
JP2006528969A (ja) 2006-12-28
ES2272914T3 (es) 2007-05-01
WO2004103350A1 (en) 2004-12-02
CN1791390A (zh) 2006-06-21

Similar Documents

Publication Publication Date Title
DE60308828D1 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
DE60226012D1 (de) Geschmacksmaskierte pharmazeutische formulierungen
DK0939626T3 (da) Galenisk form til forlænget frigivelse af milnacipran
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
BR0308609A (pt) revestimento de semente de nitrogênio de liberação lenta
EE03904B1 (et) Graanul, farmatseutiline doseerimisvorm, graanulite valmistamismeetod ja ravimiga kaetud graanulid
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
AU2003208018A1 (en) Drug release from antithrombogenic multi-layer coated stent
DK1519717T3 (da) Sammensætning til kontrolleret frisætning
DE50012448D1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
HRP20040367B1 (en) Montelukast granule formulation
MXPA02009547A (es) Composicion de vitamina de liberacion sostenida.
DE60321386D1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
DE60323474D1 (de) Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
WO2006035418A3 (en) Microcapsules comprising a methylxanthine and a corticosteroid
NO308303B1 (no) Vannløselige rapamycinestere, anvendelse derav samt farmasøytisk blanding som omfatter forbindelsene
ATE244002T1 (de) Pharmazeutische formulierung mit omeprazol
UA84140C2 (ru) Дисперсия кристаллов или гранул активного вещества с маскированным вкусом, жевательные мягкие капсулы, заполненные указанной дисперсией, и способ их приготовления
WO2005097064A3 (en) Taste-masked drugs in rupturing multiparticulates
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
CO5160317A1 (es) Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene
ATE350021T1 (de) Pharmazeutische formulierung enthaltend trägerkügelchen mit aufgebrachter schicht aus valaciclovir
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties